Page 2 - Thomas Karalis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ --Antengene recently unveiled a new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help Antengene to attract more top talents, and further accelerate its expansion in the APAC region as well as its committed efforts to bring high quality and affordable innovative medicines to patients with life-threatening conditions including hematologic malignancies and solid tumors in Asia Pacif...

In Australia around 2,400 people are diagnosed each year with multiple myeloma (MM), and around 20,000 patients are living with MM at any given time. 

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. -...

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma - read this article along with other careers information, tips and advice on BioSpace

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. - XPOVIO®, in combination with dexamethasone (Xd), gives patients with triple class refractory multiple myeloma, a new treatment option. These patients have poor prognosis and limited treatment options. - XPOVIO® is the first of a new class...